Not following you there, or perhaps you missed my point - ie. If Japanese patients don't get reimbursed for the product, the US market should further exceed market penetration in comparison (on top of the larger US market).
Ann: Botanix $40 Million Capital Raising for Sofdra Rollout, page-246
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.0¢ | 30.0¢ | $2.131M | 7.020M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 504695 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 38124 | 3 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |